Record Global Revenues
Global revenues reached USD 16.1 million, marking the second consecutive quarter with record overall quarterly revenue.
Significant HIFU Revenue Growth
HIFU revenue reached USD 7.7 million, a 57% increase compared to the third quarter of last year.
Focal One Placement Success
Recorded 8 Focal One placements, showing a 167% increase compared to the same period last year.
Peer-Reviewed Scientific Study
A study published in the Journal of International Urology and Nephrology showed HIFU delivered non-inferior 10-year oncological outcomes compared to external beam radiation therapy.
Reimbursement Progress
Meaningful progress in reimbursement coverage with commercial payers, particularly among Medicare Advantage providers.
Endometriosis Clinical Evidence
Phase III RCT showed significant improvement in symptom scores for patients treated with HIFU, with 85% of sham group patients opting for treatment post-unblinding.
2025 Industry Award
Focal One received the 2025 Industry Award for innovations in Endourological Instrumentation at the World Congress of Endourology and Uro-Technology.